REGENERON PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
REGENERON PHARMACEUTICALS, INC. (REGN) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $47.80 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-07.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2014-12-31 was $535.21M.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2014-09-30 was $313.31M.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2016 was $47.80M, a 94.17% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2015 was $819.66M, a 18.47% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2014 was $691.87M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $47.80M 10-K · filed 2019-02-07 | $47.79M 10-K · filed 2017-02-09 | |||
| 2015-12-31 | $819.66M 10-K · filed 2018-02-08 | ||||
| 2014-12-31 | $535.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $848.52M derived: sum of 2 quarters · filed 2017-02-09 | $691.87M 10-K · filed 2017-02-09 | ||
| 2014-09-30 | $313.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $156.66M 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | -$156.65M 10-Q · filed 2014-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |